Citigroup Maintains Neutral on Acelyrin, Lowers Price Target to $3

Benzinga · 01/07 19:58
Citigroup analyst Samantha Semenkow maintains Acelyrin (NASDAQ:SLRN) with a Neutral and lowers the price target from $6 to $3.